期刊文献+

曲安奈德辅助玻璃体后皮质可视化在玻璃体切割术中的应用 被引量:2

Application of triamcinolone acetonide assisted visualization of posterior cortex of vitreous body in vitrectomy
下载PDF
导出
摘要 目的探讨曲安奈德(triamcinolone acetonide,TA)注射液在玻璃体手术中辅助剥除玻璃体皮质的作用。方法对108例(126眼)患者行玻璃体切割术,术中切除中央部玻璃体后,向玻璃体内注入0.5mL TA混悬液,对后极部视网膜表面可能残存的玻璃体进行标识,将黏附TA颗粒的视网膜皮质切除。结果 TA辅助玻璃体切割术中残余玻璃体清晰可见,TA乳白色颗粒黏附于视网膜表面的残留玻璃体皮质的部位及范围,更易于辨认及剥除。治疗后平均视力0.2931±0.1231,高于术前0.1423±0.0485。结论 TA在玻璃体切割术中的应用有助于辨别残留的玻璃体皮质,提高了手术的安全性,缩短了手术时间。 Objective To investigate the effect of triamcinolone acetonide(TA) injection on assisting to remove cortex of vitreous body during vitrectomy. Methods About 108 patients(126 eyes) were taken vitrectomy.After removing vitreous body at the central part,0.5 mL TA suspension was injected into vitreous space.The remaining vitreous body at rear retinal surface was marked.The retinal cortex with TA particles was removed. Results The section and scope of remaining cortex of vitreous body at retinal surface were clearly visible and recognized in vitrectomy with auxiliary TA injection,so it was easy to be removed.The mean visual acuity was 0.293 1±0.123 1 before treatment,which was higher than 0.142 3±0.048 5 before treatment. Conclusion The application of TA injection in vitrectomy helps to identify residues,improves safety of operation,and shortens operating time.
出处 《眼科新进展》 CAS 北大核心 2011年第4期382-383,共2页 Recent Advances in Ophthalmology
关键词 曲安奈德 玻璃体 切割术 triamcinolone acetonide; vitreous body; vitrectomy;
  • 相关文献

参考文献3

二级参考文献27

  • 1王丽丽,朱忠桥,王勇,王海燕.曲安奈德预防术后增殖性玻璃体视网膜病变临床观察[J].国际眼科杂志,2005,5(4):685-687. 被引量:19
  • 2Kumagai K. Introduction of a new method for the preparation of triamcinolone acctonide solution as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina, 2003, 23(6):881-882.
  • 3Jonas JB, Sofker A, Hayler J, et al. lntravitreal crystalline triamcinolone acetonide as an additional tool in pars plana vitrectomy for complicated proliferative vitreoretinopathy? Acta Ophthalmol Scand, 2003,81 (6) :663-665.
  • 4Sakamoto T, Miyazaki M, Hisatomi T, et al. Triamcinolone-assisted pars plana vitrectomy improves the surgical procedures and decreases the postoperative blood-ocular barrier breakdown. Graefes Arch Clin Exp Ophthalmol, 2002, 240(6):423-429.
  • 5Hollborn M, Birkenmeier G, Saalbach A, et al. Expression of LRP1 in retinal pigment epithelial cells and its regulation by growth factors. Invest Ophthalmol Vis Sci, 2004, 45(6) :2033-2038.
  • 6Enaida H, Hata Y, Ueno A, et al. Possible benefits of triamcinolone-assisted pars plana vitrectomy for retinal diseases. Retina, 2003,23(6) :764-770.
  • 7Furino C, Micelli Ferrari T, Boscia F, et al. Triamcinolone-assisted pars plana vitrectomy for proliferative vitreoretinopathy. Retina,2003, 23(6) :771-776.
  • 8Jonas JB. Intravitreal triamcinolone acetonide as treatment for extensive exudative retinal detachment. Br J Ophthalmol, 2004, 88(4) :587-588.
  • 9Enaida H, Sakamoto T, Ueno A, et al. Submacular deposition of triamcinolone acetonide after triamcinolone-assisted vitrectomy. Am J Ophthalmol, 2003, 135(2) :243-246.
  • 10Matsumoto H, Enaida H, Hisatomi T, et al. Retinal detachment in morning glory syndrome treated by triamcinolone acetonide-assisted pars plana vitrectomy. Retina, 2003, 23(4):569-572.

共引文献36

同被引文献10

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部